Kardigan
IPOCardiovascular Drug Development for Heart Health
United States · $554.0M raised
- Business Model
- B2B
- Website
- kardigan.bio
- Total Funding
- $554.0M
- Last Round
- $254.0M Series BOct 2025
- Rounds
- 2
About
Cardiovascular drug development company focused on making cardiovascular disease curable and preventable through targeted treatments.
Summary
Kardigan is a Biotech company based in United States. It has raised $554.0M in total across 2 rounds, most recently a $254.0M Series B round in Oct 2025. Investors include ARCH Venture Partners, Sequoia Heritage and Fidelity Management & Research Company.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...